DNAJB8 Antibody
Description
Introduction to DNAJB8 and Its Antibody
DNAJB8, a member of the DNAJ/HSP40 family, functions as a molecular chaperone, regulating HSP70 activity and suppressing polyglutamine protein aggregation . It is recognized as a cancer-testis antigen and a cancer stem cell antigen, particularly in renal cell carcinoma and sarcomas . The DNAJB8 antibody is a research and therapeutic tool targeting this protein, with applications in immunotherapy, diagnostics, and mechanistic studies.
2.1. Therapeutic scFv Antibodies
A study isolated scFv clones (A10 and B10) reactive to the HLA-A24/DNAJB8 peptide complex using phage-display libraries . These clones demonstrated:
-
Strong binding affinity (Kd = 2.96 × 10⁻⁹ M and 5.04 × 10⁻⁹ M for A10 and B10, respectively).
-
Cytotoxicity against HLA-A24+/DNAJB8+ renal cell carcinoma and sarcoma cells via complement-dependent cytotoxicity (CDC) and bispecific antibody-dependent cellular cytotoxicity (BADCC) .
3.1. Immunotherapy
Engineered scFv antibodies (A10-hIgG1 and B10-hIgG1) showed potent CDC activity, suggesting their potential as targeted therapies for DNAJB8-expressing cancers . Bispecific formats (e.g., CD3xJB8) enhanced T-cell-mediated cytotoxicity, highlighting their promise for immunotherapy .
3.2. Diagnostics and Biomarker Research
DNAJB8 levels in serum small extracellular vesicles (sEVs) correlate with oxaliplatin resistance in colon cancer, making it a potential biomarker . The 17071-1-AP antibody has been used to detect DNAJB8 in HeLa cells and human brain tissue .
3.3. Mechanistic Studies
The antibody has aided investigations into DNAJB8’s role in:
-
Promoting chemotherapy resistance via TP53 stabilization and MDR1 upregulation .
-
Inhibiting pseudorabies virus replication through autophagy pathways .
Future Directions
-
Therapeutic Optimization: Enhancing antibody stability and tumor penetration for clinical use.
-
Biomarker Development: Expanding sEV-based diagnostics to other cancers.
-
Basic Research: Elucidating DNAJB8’s structural dynamics (e.g., oligomerization ) to refine antibody targeting.
This antibody represents a critical tool for advancing cancer research and therapy, with ongoing studies poised to expand its clinical utility.
Product Specs
Target Background
- DNAJB8 plays a critical role in the protein aggregation and degradation system. It maintains the Parkin C289G mutant protein in a soluble, degradation-competent form. PMID: 27713507
- Studies indicate that DNAJB8 expression is induced by heat shock stress, leading to an increase in side population cells and cancer stem-like cells. PMID: 29316077
- Research suggests that DNAJB8 is expressed and plays a role in colorectal cancer stem-like cells (CSCs) and cancer initiating cells (CICs), making it a potential target for CSC/CIC-targeting immunotherapy. PMID: 24450541
- DNAJB6 and DNAJB8 suppress polyQ protein aggregation by directly binding to the polyQ tract. PMID: 23612975
- DNAJB8 contributes to cancer stem-like cell (CSC) maintenance and holds promise as a target for CSC-targeting immunotherapy in renal cell carcinoma. PMID: 22552285
- DNAJB6b and DNAJB8 are particularly effective suppressors of aggregation and toxicity associated with disease-related polyglutamine proteins. PMID: 20159555
